Clinical predictors of mortality in patients with pseudomonas aeruginosa infection

PLoS One. 2023 Apr 28;18(4):e0282276. doi: 10.1371/journal.pone.0282276. eCollection 2023.

Abstract

Background: Infections caused by Pseudomonas aeruginosa are difficult to treat with a significant cost and burden. In Lebanon, P. aeruginosa is one of the most common organisms in ventilator-associated pneumonia (VAP). P. aeruginosa has developed widespread resistance to multiple antimicrobial agents such as fluoroquinolones and carbapenems. We aimed at identifying risk factors associated for P. aeruginosa infections as well as identifying independent risk factors for developing septic shock and in-hospital mortality.

Methods: We used a cross-sectional study design where we included patients with documented P. aeruginosa cultures who developed an infection after obtaining written consent. Two multivariable regression models were used to determine independent predictors of septic shock and mortality.

Results: During the observed period of 30 months 196 patients were recruited. The most common predisposing factor was antibiotic use for more than 48 hours within 30 days (55%). The prevalence of multi-drug resistant (MDR) P. aeruginosa was 10%. The strongest predictors of mortality were steroid use (aOR = 3.4), respiratory failure (aOR = 7.3), identified respiratory cultures (aOR = 6.0), malignancy (aOR = 9.8), septic shock (aOR = 18.6), and hemodialysis (aOR = 30.9).

Conclusion: Understanding resistance patterns and risk factors associated with mortality is crucial to personalize treatment based on risk level and to decrease the emerging threat of antimicrobial resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Cross-Sectional Studies
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Pneumonia, Ventilator-Associated* / epidemiology
  • Pseudomonas Infections* / epidemiology
  • Pseudomonas aeruginosa
  • Retrospective Studies
  • Shock, Septic* / drug therapy

Substances

  • Anti-Bacterial Agents

Grants and funding

This study was supported by the Medical Practice Plan, American University of Beirut, in the form of a grant to ZAK [320153].